FDA report cites risks of anemia drugs for cancer patients

An FDA staff report raised concerns about risks to cancer patients from anemia drugs such as Amgen's Aranesp and Johnson & Johnson's Procrit. The FDA cited results from five trials showing decreased survival times for patients receiving the drugs, compared with patients getting blood transfusions. An advisory panel is scheduled to meet Thursday to consider stricter labeling for the drugs.

View Full Article in:

Los Angeles Times (tiered subscription model) · Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Director, Payer Marketing
Avalere Health
Washington, DC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX